Maybe we get some good news and nice surprises more regularly over the coming months. Seems the company is flagging PW will stand down at some point. I imagine he needs a change, new challenge or a rest. Hope it a gradual process and perhaps a seat on the board? End of quarter sales will hopefully show some significant USA sales and revenue as the next catalyst. Once the phase 2 XP trial commences, it will give some more safety data in a new sensitive cohort. Also looking forward to the penumbra targets. Perhaps a couple of months away? They have been flagging some inorganic growth for some time now so I imagine they know what they are after and will take an opportunity should it arise. I don’t see any negatives but then that’s half glass full for you!! GLTA
Ann: Presentation - Value in the Vines Investor Conference, page-3
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.55 |
Change
-0.170(1.15%) |
Mkt cap ! $728.6M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.27 | $1.051M | 72.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 293 | $14.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.59 | 293 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |